For example, Davis et al. [23] reported a dramatic species shift in candidaemia isolates on an ICU over a 3-year period, during which period C. glabrata increased from virtually 0% to 30% and C. tropicalis essentially disappeared from the panel. Interestingly, a recent study on surgical ICU patients in a large centre found that use of fluconazole in terms of prophylaxis does not change the species LGK974 distribution: there was no increase in C. glabrata colonisation or in the proportion of IC caused by C. glabrata after 3 years of routine fluconazole
prophylaxis in selected patients.24 This is in contrast to the common notion that selective pressure exerted by routine prophylactic and therapeutic use of fluconazole promotes a shift towards Candida species with reduced fluconazole susceptibility. That exposure to antifungals is indeed able to change the species distribution is evidenced by an analysis performed by Sipsas et al. [25] showing a shift towards C. parapsilosis and C. tropicalis over 6 years in a patient sample that mostly included breakthrough cases after antifungal pretreatment. In this sample, C. parapsilosis fungaemia was highly significantly associated PI3K inhibitor with prior use of caspofungin. Comparing patients of different
ages, there is a markedly skewed distribution of C. glabrata being clearly associated with older age (Table 2), and C. parapsilosis showing the highest incidences in neonates
and infants. Candida albicans is by far the most prominent species in young adults with a gradual decline towards higher age groups.26 Striking differences are evident in the species distribution in intensive care and solid tumour patients in comparison with haematological patients, with a substantial preponderance of C. non-albicans species in the latter group.3 Another factor affecting the species distribution is a history of hospitalisation. In one of the authors’ institution, previous inpatient stay was associated with a substantially increased rate of C. glabrata in colonising species, while colonisation status per se was more strongly affected by the length of the current stay.27 Predicting Obatoclax Mesylate (GX15-070) the species that will probably infect patients with IC may influence the therapeutic choice in patients treated empirically before a Candida spp. is definitely identified as the causative pathogen. While the species of the colonising and/or infecting strain is clearly influenced by patient characteristics (see Table 3 and sections above), studies show that certain species are independently associated with poor outcome and higher mortality. For example, work recently performed by Dimopoulos et al. [28] showed a multivariate odds ratio of 6.7 for lethal outcome in ICU patients with C. non-albicans when compared with C. albicans candidaemia. Candida species other than C. albicans were mostly C. glabrata and C. tropicalis.